281 related articles for article (PubMed ID: 31978211)
21. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT.
Zhang Z; Sun H; Dai H; Walsh RM; Imakura M; Schelter J; Burchard J; Dai X; Chang AN; Diaz RL; Marszalek JR; Bartz SR; Carleton M; Cleary MA; Linsley PS; Grandori C
Cell Cycle; 2009 Sep; 8(17):2756-68. PubMed ID: 19652553
[TBL] [Abstract][Full Text] [Related]
22. MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.
Sochalska M; Schuler F; Weiss JG; Prchal-Murphy M; Sexl V; Villunger A
Oncogene; 2017 Apr; 36(15):2066-2073. PubMed ID: 27694901
[TBL] [Abstract][Full Text] [Related]
23. Histone H2AX suppresses translocations in lymphomas of Eμ-c-Myc transgenic mice that contain a germline amplicon of tumor-promoting genes.
Fusello A; Horowitz J; Yang-Iott K; Brady BL; Yin B; Rowh MA; Rappaport E; Bassing CH
Cell Cycle; 2013 Sep; 12(17):2867-75. PubMed ID: 23966158
[TBL] [Abstract][Full Text] [Related]
24. Id2 is dispensable for myc-induced lymphomagenesis.
Nilsson JA; Nilsson LM; Keller U; Yokota Y; Boyd K; Cleveland JL
Cancer Res; 2004 Oct; 64(20):7296-301. PubMed ID: 15492249
[TBL] [Abstract][Full Text] [Related]
25. Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes.
Yang H; Li TW; Ko KS; Xia M; Lu SC
Hepatology; 2009 Mar; 49(3):860-70. PubMed ID: 19086036
[TBL] [Abstract][Full Text] [Related]
26. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites.
Hurlin PJ; Quéva C; Eisenman RN
Genes Dev; 1997 Jan; 11(1):44-58. PubMed ID: 9000049
[TBL] [Abstract][Full Text] [Related]
27. Mnt transcriptional repressor is functionally regulated during cell cycle progression.
Popov N; Wahlström T; Hurlin PJ; Henriksson M
Oncogene; 2005 Dec; 24(56):8326-37. PubMed ID: 16103876
[TBL] [Abstract][Full Text] [Related]
28. Chromatin dynamics at the hTERT promoter during transcriptional activation and repression by c-Myc and Mnt in Xenopus leavis oocytes.
Wahlström T; Belikov S; Arsenian Henriksson M
Exp Cell Res; 2013 Dec; 319(20):3160-9. PubMed ID: 23860446
[TBL] [Abstract][Full Text] [Related]
29. IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.
Vecchio E; Golino G; Pisano A; Albano F; Falcone C; Ceglia S; Iaccino E; Mimmi S; Fiume G; Giurato G; Britti D; Scala G; Quinto I
Cell Death Dis; 2019 Apr; 10(4):320. PubMed ID: 30975981
[TBL] [Abstract][Full Text] [Related]
30. EBV latent membrane protein 2A orchestrates p27
Fish K; Sora RP; Schaller SJ; Longnecker R; Ikeda M
Blood; 2017 Dec; 130(23):2516-2526. PubMed ID: 29074502
[TBL] [Abstract][Full Text] [Related]
31. Mnt: a novel Max-interacting protein and Myc antagonist.
Hurlin PJ; Qúeva C; Eisenman RN
Curr Top Microbiol Immunol; 1997; 224():115-21. PubMed ID: 9308234
[TBL] [Abstract][Full Text] [Related]
32. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.
Campbell KJ; Bath ML; Turner ML; Vandenberg CJ; Bouillet P; Metcalf D; Scott CL; Cory S
Blood; 2010 Oct; 116(17):3197-207. PubMed ID: 20631380
[TBL] [Abstract][Full Text] [Related]
33. Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome.
Toyo-oka K; Hirotsune S; Gambello MJ; Zhou ZQ; Olson L; Rosenfeld MG; Eisenman R; Hurlin P; Wynshaw-Boris A
Hum Mol Genet; 2004 May; 13(10):1057-67. PubMed ID: 15028671
[TBL] [Abstract][Full Text] [Related]
34. MYC-driven malignant transformation of mature murine B cells requires inhibition of both intrinsic apoptosis and p53 activity.
Högstrand K; Grandien A
Eur J Immunol; 2019 Mar; 49(3):375-385. PubMed ID: 30281155
[TBL] [Abstract][Full Text] [Related]
35. Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs.
Happo L; Phipson B; Smyth GK; Strasser A; Scott CL
Cell Death Dis; 2012 May; 3(5):e306. PubMed ID: 22573037
[TBL] [Abstract][Full Text] [Related]
36. BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.
Hogg SJ; Newbold A; Vervoort SJ; Cluse LA; Martin BP; Gregory GP; Lefebure M; Vidacs E; Tothill RW; Bradner JE; Shortt J; Johnstone RW
Mol Cancer Ther; 2016 Sep; 15(9):2030-41. PubMed ID: 27406984
[TBL] [Abstract][Full Text] [Related]
37. Induction of apoptosis in Eμ-myc lymphoma cells in vitro and in vivo through calpain inhibition.
Li H; Nepal RM; Martin A; Berger SA
Exp Hematol; 2012 Jul; 40(7):548-563.e2. PubMed ID: 22366408
[TBL] [Abstract][Full Text] [Related]
38. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
39. IL-6 promotes MYC-induced B cell lymphomagenesis independent of STAT3.
Petrenko O; Li J; Cimica V; Mena-Taboada P; Shin HY; D'Amico S; Reich NC
PLoS One; 2021; 16(3):e0247394. PubMed ID: 33651821
[TBL] [Abstract][Full Text] [Related]
40. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
Berg T; Thoene S; Yap D; Wee T; Schoeler N; Rosten P; Lim E; Bilenky M; Mungall AJ; Oellerich T; Lee S; Lai CK; Umlandt P; Salmi A; Chang H; Yue L; Lai D; Cheng SW; Morin RD; Hirst M; Serve H; Marra MA; Morin GB; Gascoyne RD; Aparicio SA; Humphries RK
Blood; 2014 Jun; 123(25):3914-24. PubMed ID: 24802772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
